Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...

Mississauga, Ontario Thursday, November 14, 2024, 09:00 Hrs [IST] ...

GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...

Ojjaara (momelotinib) is the only approved treatment for newly diagnosed and previously treated myelofibrosis patients i who ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Prithviraj Bose, MD, discusses the most critical adverse effects seen with each of the 4 approved JAK inhibitors for the treatment of myeloproliferative neoplasms.

Oncology sales rose 94%, driven by strong patient demand for Jemperli, Ojjaara and Zejula. Jemperli added £130 million to GSK’s top line compared with £108 million in second-quarter 2024 ...

GSK plc GSK reported third-quarter 2024 core earnings of $1.27 per American depositary share (ADS), which beat the Zacks Consensus Estimate of $1.16. Core earnings declined 1% year over year on a ...

A council plans on battling “the plague” of shopping trolleys dumped in its rivers and streets by hitting supermarkets harder in the pocket. A wildlife reserve visitor centre has been damaged ...